iGMDRD310
Canonical SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC
InChI: InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChI Key: HKVAMNSJSFKALM-GKUWKFKPSA-N
Loading, please wait...
Standard Name | CHEMBL | Pubchem CID | DRUGBANK ID | Drug Status | Drug targets (TTD) | Drug Type |
---|---|---|---|---|---|---|
Standard NameEverolimus CHEMBLCHEMBL1908360 Pubchem CID6442180 DRUGBANK IDDB01590 Drug StatusAlone Drug targets (TTD)DAP001223 Drug TypeSmall Molecule |
Drug Class:
Anti-Bacterial AgentsAntineoplastic AgentsAntineoplastic and Immunomodulating AgentsCYP3A Substrates (Sensitive)Cytochrome P-450 CYP3A SubstratesHyperglycemia-Associated AgentsImmunologic FactorsImmunosuppressive AgentsKinase InhibitorLactonesMacrocyclic CompoundsMacrolidesmTOR Inhibitor ImmunosuppressantMyelosuppressive AgentsPolycyclic CompoundsPolyketidesProtein Kinase InhibitorsSelective ImmunosuppressantsSirolimusDrug Targets:
MTOR (P42345)Drug-model tissue-cancer distribution: Bubble Plot
Drug-gene pathway enrichments
Drug-gene GO enrichments
Drug-Gene: Aster Plot
Gene in drug-gene network: Network Plot

Models in Everolimus
Loading, please wait...
Model | Level | Reference ID | Tissue | Cancer | Drug | Clinical Response | Source | |
---|---|---|---|---|---|---|---|---|
No matching records found |